139.08
price up icon1.52%   2.08
after-market Dopo l'orario di chiusura: 139.08
loading
Precedente Chiudi:
$137.00
Aprire:
$137.87
Volume 24 ore:
683.96K
Relative Volume:
0.77
Capitalizzazione di mercato:
$13.79B
Reddito:
$2.41B
Utile/perdita netta:
$305.80M
Rapporto P/E:
47.15
EPS:
2.95
Flusso di cassa netto:
$492.20M
1 W Prestazione:
+1.52%
1M Prestazione:
-3.28%
6M Prestazione:
+58.88%
1 anno Prestazione:
+24.56%
Intervallo 1D:
Value
$136.10
$139.74
Intervallo di 1 settimana:
Value
$135.59
$141.14
Portata 52W:
Value
$84.23
$154.61

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
Nome
Neurocrine Biosciences Inc
Name
Telefono
(858) 617-7600
Name
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
Dipendente
1,800
Name
Cinguettio
Name
Prossima data di guadagno
2024-10-30
Name
Ultimi documenti SEC
Name
NBIX's Discussions on Twitter

Confronta NBIX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
139.08 13.59B 2.41B 305.80M 492.20M 2.95
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
143.49 63.27B 9.39B 2.62B 2.22B 5.8121
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.31 45.67B 29.96B 957.25M 4.77B 0.2956
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.04 39.27B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
20.21 23.02B 16.70B -157.13M 1.19B -0.1446
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
448.93 20.66B 3.08B 1.24B 1.07B 25.61

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-21 Iniziato Truist Buy
2025-07-10 Iniziato Goldman Buy
2025-04-15 Aggiornamento Needham Hold → Buy
2025-04-14 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2025-02-11 Iniziato Deutsche Bank Hold
2024-10-10 Ripresa Raymond James Outperform
2024-08-29 Aggiornamento Piper Sandler Neutral → Overweight
2024-04-24 Aggiornamento Wells Fargo Equal Weight → Overweight
2023-12-13 Ripresa Citigroup Neutral
2023-12-12 Iniziato Deutsche Bank Buy
2023-10-24 Ripresa Cantor Fitzgerald Overweight
2023-08-21 Reiterato Mizuho Neutral
2023-07-24 Aggiornamento SVB Securities Market Perform → Outperform
2023-07-06 Aggiornamento BMO Capital Markets Underperform → Market Perform
2023-05-04 Aggiornamento Guggenheim Neutral → Buy
2023-03-30 Aggiornamento Canaccord Genuity Hold → Buy
2023-03-03 Aggiornamento Evercore ISI In-line → Outperform
2023-02-03 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2022-11-14 Downgrade Evercore ISI Outperform → In-line
2022-10-11 Iniziato UBS Buy
2022-09-26 Iniziato Wells Fargo Equal Weight
2022-06-06 Ripresa Jefferies Buy
2022-03-03 Downgrade Piper Sandler Overweight → Neutral
2022-02-25 Aggiornamento Goldman Neutral → Buy
2022-01-18 Downgrade RBC Capital Mkts Outperform → Sector Perform
2021-11-19 Iniziato BMO Capital Markets Underperform
2021-11-17 Aggiornamento JP Morgan Neutral → Overweight
2021-10-14 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-09-23 Ripresa Needham Hold
2021-08-06 Downgrade Canaccord Genuity Buy → Hold
2021-05-18 Ripresa Goldman Neutral
2021-05-06 Aggiornamento Barclays Equal Weight → Overweight
2021-02-02 Iniziato Raymond James Outperform
2020-09-30 Iniziato The Benchmark Company Hold
2020-08-04 Downgrade JP Morgan Overweight → Neutral
2020-06-29 Downgrade Goldman Buy → Neutral
2020-06-09 Iniziato Wedbush Outperform
2020-03-06 Iniziato Citigroup Buy
2020-02-27 Iniziato Barclays Equal Weight
2020-02-24 Iniziato William Blair Outperform
2020-02-06 Iniziato Mizuho Neutral
2020-02-05 Reiterato H.C. Wainwright Buy
2019-12-13 Downgrade Credit Suisse Outperform → Neutral
2019-08-07 Iniziato RBC Capital Mkts Outperform
2019-07-16 Iniziato Oppenheimer Outperform
2019-06-05 Iniziato Guggenheim Neutral
2019-05-21 Iniziato Credit Suisse Outperform
2019-04-22 Aggiornamento JP Morgan Neutral → Overweight
2019-04-12 Iniziato Evercore ISI Outperform
2019-02-06 Reiterato BofA/Merrill Buy
2019-01-23 Downgrade JP Morgan Overweight → Neutral
2018-12-13 Iniziato Goldman Buy
2018-11-21 Iniziato Canaccord Genuity Buy
Mostra tutto

Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie

pulisher
08:02 AM

RBC Lifts Price Target on Neurocrine Biosciences to $156 From $149, Keeps Outperform Rating - MarketScreener

08:02 AM
pulisher
06:29 AM

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results - Eastern Progress

06:29 AM
pulisher
Oct 07, 2025

Q3 2025 Results: Neurocrine Biosciences to Host Oct. 28 Webcast & Call at 1:30 p.m. PT; Replay 1 Month - Stock Titan

Oct 07, 2025
pulisher
Oct 07, 2025

How New Three-Year INGREZZA Data at Neurocrine Biosciences (NBIX) Has Changed Its Investment Story - simplywall.st

Oct 07, 2025
pulisher
Oct 07, 2025

A Fresh Look at Neurocrine Biosciences (NBIX) Valuation After Latest INGREZZA Clinical Study Results - Yahoo Finance

Oct 07, 2025
pulisher
Oct 06, 2025

Earnings call transcript: Neurocrine Q2 2025 shows strong sales growth By Investing.com - Investing.com Australia

Oct 06, 2025
pulisher
Oct 06, 2025

Neurocrine Biosciences names Mike Sibley to lead neuropsychiatry franchise By Investing.com - Investing.com Nigeria

Oct 06, 2025
pulisher
Oct 06, 2025

Neurocrine reports sustained benefits of INGREZZA for Huntington’s chorea By Investing.com - Investing.com Nigeria

Oct 06, 2025
pulisher
Oct 06, 2025

Neurocrine Biosciences names Mike Sibley to lead neuropsychiatry franchise - Investing.com

Oct 06, 2025
pulisher
Oct 06, 2025

20+ years commercial leader Mike Sibley named Neurocrine SVP & GM, Neuropsychiatry to lead INGREZZA franchise - Stock Titan

Oct 06, 2025
pulisher
Oct 06, 2025

Earnings call transcript: Neurocrine Q2 2025 shows strong sales growth - Investing.com India

Oct 06, 2025
pulisher
Oct 06, 2025

Is Neurocrine Biosciences Inc. a candidate for recovery playJuly 2025 Update & Low Drawdown Trading Techniques - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

What MACD signals say about Neurocrine Biosciences Inc.Insider Selling & Smart Allocation Stock Tips - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Intraday pattern recognizer results for Neurocrine Biosciences Inc.2025 Market Overview & Daily Price Action Insights - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Neurocrine reports sustained benefits of INGREZZA for Huntington’s chorea - Investing.com

Oct 06, 2025
pulisher
Oct 06, 2025

Neurocrine shows 3-year safety data for Huntington's drug INGREZZA - StreetInsider

Oct 06, 2025
pulisher
Oct 06, 2025

Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea - PR Newswire

Oct 06, 2025
pulisher
Oct 06, 2025

Technical signs of recovery in Neurocrine Biosciences Inc.Weekly Market Report & Risk Controlled Daily Trade Plans - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Will Neurocrine Biosciences Inc. stock deliver consistent dividends2025 Year in Review & Daily Stock Trend Reports - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

What the G7 Rare Earths News Means for Neurocrine Biosciences Valuation in 2025 - simplywall.st

Oct 05, 2025
pulisher
Oct 05, 2025

Will Neurocrine Biosciences Inc. benefit from macro trends2025 Short Interest & Real-Time Volume Triggers - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Will Neurocrine Biosciences Inc. (NB3) stock see valuation expansionEarnings Summary Report & Free Community Consensus Stock Picks - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Why Neurocrine Biosciences Inc. (NB3) stock fits value portfolios2025 Market Sentiment & Free High Accuracy Swing Entry Alerts - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

What momentum shifts mean for Neurocrine Biosciences Inc.2025 Valuation Update & Fast Exit/Entry Strategy Plans - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Is Neurocrine Biosciences Inc. (NB3) stock a buy during volatile marketsFed Meeting & Reliable Price Action Trade Plans - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Why Neurocrine Biosciences Inc. stock is trending among retail traders2025 Market Outlook & Capital Efficient Trade Techniques - newser.com

Oct 05, 2025
pulisher
Oct 04, 2025

Neurocrine (NBIX) Gets a Buy from Bank of America Securities - The Globe and Mail

Oct 04, 2025
pulisher
Oct 03, 2025

Neurocrine Biosciences (NBIX): Exploring Valuation After Recent Share Price Movement - simplywall.st

Oct 03, 2025
pulisher
Oct 03, 2025

Can Neurocrine Biosciences Inc. stock maintain growth trajectoryPortfolio Update Report & Verified Momentum Stock Alerts - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Will breakout in Neurocrine Biosciences Inc. lead to full recoveryRate Cut & Safe Entry Point Identification - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Should I buy Neurocrine Biosciences Inc. (NB3) stock before earnings seasonWeekly Market Report & AI Enhanced Trade Execution Alerts - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Why Neurocrine Biosciences Inc. stock could benefit from AI revolutionCEO Change & Long-Term Safe Investment Plans - newser.com

Oct 03, 2025
pulisher
Oct 01, 2025

Iambic Therapeutics Announces the Addition of Shalini Sharp to its Board of Directors - Business Wire

Oct 01, 2025

Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$58.17
price up icon 0.35%
drug_manufacturers_specialty_generic RDY
$13.99
price down icon 0.29%
$9.97
price down icon 1.68%
$20.34
price down icon 0.54%
$448.93
price down icon 1.73%
Capitalizzazione:     |  Volume (24 ore):